EMM Disclosure
March 27 2003 - 5:55AM
UK Regulatory
RNS Number:2834J
GoldmanSachs International
27 March 2003
EMM DISCLOSURE
FORM 38.5 (SUMMARY)
Lodge with a RIS and the Takeover Panel. Use a separate form for each class of
securities in which dealings have been made.
CONNECTED EXEMPT MARKET- MAKERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Name of EMM
Goldman Sachs International
Date of disclosure
27 March 2003
Contact name
Peter Highton
Telephone number
+44 207-774-1935
Please see attached disclosure of dealings under Rule 38.5 in the securities of
the following companies:
Cambridge Antibody Technology Group plc
AMENDMENT
If the attached Rule 38.5 disclosure is to amend a previous disclosure, please
state which element(s) of previous disclosure was incorrect:
In the case of option business or dealings in derivatives full details should be
given on a separate sheet so that the nature of the dealings can be fully
understood. For options this should include the number of securities under
option, the exercise period (or in the case of exercise, the exercise date), the
exercise price and any option money paid or received. For derivatives this
should include, at least, the number of reference securities to which they
relate (when relevant), the maturity date (or if applicable the closing out
date) and the reference price.
For full details of the disclosure requirements see Rules 8 and 38 of the Code.
If in doubt contact the Monitoring Section of the Panel, Tel. No: 020 7638 0129.
Email: monitoring@disclosure.org.uk
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
18 February 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
5,000 (customer sold to close)
CFD closing out price
3.4466 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
23 February 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
5,000 (customer sold to close)
CFD closing out price
3.3496 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
18 February 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
25,000 (customer sold to close)
CFD closing out price
3.4224 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
23 February 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
5,000 (customer sold to close)
CFD closing out price
3.3496 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
24 February 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
5,000 (customer sold to close)
CFD closing out price
3.3496 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
27 February 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
3,800 (customer sold to close)
CFD closing out price
3.3496 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
1 January 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
8,367 (customer sold to close)
CFD closing out price
3.3496 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Dealing in Contract for Difference ("CFD") referenced to
Cambridge Antibody Technology Group plc Ordinary Shares
Date of disclosure
27 March 2003
Date of dealing
26 March 2003
Name of EMM/EPT
Goldman Sachs International
Name of offeree/offeror with whom connected
Oxford Glycosciences plc
Product Type
Long CFD
Maturity Date
2 January 2013
Writing of CFD
Number of ordinary shares to which the CFD is referenced
0
CFD reference price
0.00 # Sterling
Closing out of CFD
Number of ordinary shares to which the CFD is referenced
9,000 (customer sold to close)
CFD closing out price
3.3496 # Sterling
Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.
This information is provided by RNS
The company news service from the London Stock Exchange
END
EMMSEDFFWSDSEID